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Abstract
Objective: The objective of this EBM review is to determine whether or not crizotinib works better
in reducing the chest pain of ALK-positive non-small cell lung cancer (NSCLC) patients compared
with chemotherapy.
Study Design: This paper evaluates three randomized controlled trials (RCTs), which were all
published in peer-reviewed journals in English after 2013.
Data Sources: Three RCTs comparing the efficacy of crizotinib in reducing the chest pain in ALKpositive non-small cell lung cancer patients with chemotherapy including pemetrexed and
docetaxel. Articles were selected via PubMed based on the outcomes of the studies mattered to
patients (POEM).
Outcomes Measured: The European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire 13-item lung cancer module (EORTC QLQ-LC13) was completed by
patients, the scores were used to measure lung cancer specific symptoms including chest pain.
Results: All the three RCTs articles (Shaw 2013, Solomon, 2014, Blackhall 2014) showed that
crizotinib is more effective in decreasing the chest pain in ALK-positive NSCLC patients than
chemotherapy (P<0.001 [pemetrexed or docetaxel], P<0.001 [pemetrexed], P<0.05 [pemetrexed]
and P<0.001 [docetaxel]). All these studies suggest that crizotinib is superior to chemotherapy
(pemetrexed or docetaxel) in reducing chest pain for ALK-positive NSCLC patients.
Conclusions: The data analysis of these studies indicates crizotinib works better in reducing the
chest pain in ALK-positive NSCLC patients compared with chemotherapy including pemetrexed
and docetaxel. The studies are limited to ALK-positive NSCLC patients. The treatments in the
studies are not double-blinded, chest pain could be caused by other factors such as anxiety, which
were not evaluated in this study.
Key Words: crizotinib, ALK-positive NSCLC, chest pain, chemotherapy.
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Introduction
The cell is the basic unit in the human body, it normally goes through growth, proliferation,
differentiation, and death. When a series of genetic changes occur in the cells, they gain the ability
to escape from the cell division and cell death control. Uncontrolled cell growth could form a
tumor (solid tumor) or generate many immature cells (liquid tumor). Cancer occurs when the
tumor becomes invasive and spreads to nearby tissues or even distant organs. Cancer cells affect
the normal organs function, eventually cause organ failure and death.
Cancer can occur almost anywhere in the body. Lung cancer is an abnormal overgrowth
of lung tissue cells, may spread to lymph nodes and other organs such as the liver, brain, or bone.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two major types of
lung cancer.1 More than 80% of lung cancers are NSCLC which includes adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma.1 Adenocarcinoma is the most common form
of lung cancer in the United States for both men and women which arises from the glandular tissue
that lines inside of the lung.1 Anaplastic lymphoma kinase (ALK) gene encodes ALK receptor
tyrosine kinase which actives a signaling pathway that plays an important role in regulating cell
growth.2,3 ALK gene mutation involved NSCLC is called ALK-positive NSCLC. The majority of
ALK-positive NSCLC patients are young, female, and normally diagnosed before 50.4 The most
common risk factor for NSCLC is smoking, however, ALK-positive NSCLC was found to have no
strong association with smoking or environmental toxins.4
Lung cancer is the 2nd most common cancer and the leading cause of cancer death in both
men and women in the United States.5 The Centers for Disease Control and Prevention (CDC)
statistical study shows 218,229 new cases of lung cancer in the United States in 2016.6 NSCLC
is accounting for 85% of all lung cancer, and about 1 of 25 NSCLC patients is ALK-positive
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NSCLC.7,8 The national expenditure of NSCLS was approximately $13.6 billion in the United
States in 2016.9 The American Cancer Society estimates about 228,150 new lung cancer cases
and about 142,670 deaths from lung cancer in 2019 in the United States.5
Early stage lung cancer is normally asymptomatic; the symptoms in advanced lung cancer
include cough, coughing up blood, shortness of breath, unintentional weight loss, chest pain,
hoarseness, bone pain, and headache.10 The chest pain is one of the most common symptoms.
Surgery is the standard treatment for localized NSCLC; radiation therapy is usually used
before surgery to shrink lung tumor or after surgery to kill any possible missed tumor.11
Combination platinum-based chemotherapy such as carboplatin and paclitaxel or carboplatin and
pemetrexed are commonly used for locally advanced NSCLC, metastatic NSCLC, or after
surgery.12 Chemotherapy generally targets fast-growing and dividing cells which is not specific
and works throughout the body. In the past decade, targeted therapies are used to treat patients
based on the characteristics of the tumor, molecular tests are used to determine the gene mutations
or rearrangements and guide the treatment.13

Another cancer treatment approach, called

immunotherapy or biologic therapy, is used to boost the body’s immune system to fight cancer
cells.14
Crizotinib is the first targeted therapy drug designed for ALK-positive NSCLC by targeting
both MET and ALK receptor tyrosine kinases.15 Studies have shown crizotinib significantly
increases progression-free survival time in ALK-positive NSCLC patients compared with
chemotherapy (pemetrexed and docetaxel).16,17,18 As the progression-free survival time in ALKpositive NSCLC patients prolonged in crizotinib treatment group, it is reasonable to predict that
crizotinib improves key lung-cancer symptoms (cough, dyspnea, chest pain, and fatigue) and
overall quality of life as well.
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Objective
The objective of this systematic review is to determine whether or not crizotinib works
better in reducing the chest pain of ALK-positive non-small cell lung cancer patients compared
with chemotherapy.

Methods
This paper evaluates three randomized controlled trials comparing the efficacy of crizotinib
in reducing the chest pain in ALK-positive non-small cell lung cancer patients with chemotherapy.
The patients of the review are the age of 18 years or older with locally advanced or
metastatic NSCLC that was positive for an ALK rearrangement.16,17,18 The Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 was used to evaluate the patients, characteristics
of the patients include age, sex, race, smoking status, histology of disease, Eastern Cooperative
Oncology Group performance status, extent of disease, and brain metastases.19 Two comparison
groups of patients are evaluated, one never had chemotherapy and another group had one prior
platinum-based chemotherapy regimen. In this review one of the most common lung cancer
symptoms — the chest pain — is primarily evaluated by comparing crizotinib treatment or
chemotherapy.
The three randomized controlled trials (RCTs) for this review were searched via PubMed,
the articles were selected based on the outcomes of the studies mattered to patients (POEM). All
the articles were published in peer-reviewed journals and written in English. Other criteria for the
studies include RCT studies published after 2013 and the exclusion of non-ALK-positive NSCLC
or SCLC patients. Keywords used in searching the articles are: crizotinib, ALK-positive NSCLC,
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chest pain, and chemotherapy. Summary of statistics was reported as mean, SD, and p-value.
Demographics and characteristics of this study are as follow (Table 1):
Table 1. Demographics and Characteristics
Study

Type

# Pts

Inclusion
Criteria
Pts with
ALKpositive
NSCLC
who had
received
one prior
platinumbased
regimen.

Exclusion
criteria
Pts with
ALKpositive
NSCLC
who had
received
no
previous
systemic
treatment.

W/D

Interventions

347

Age
(yrs)
22-85

Shaw, 2013
(1)

RCT

180

RCT

343

19-78

Pts with
ALKpositive
NSCLC
who had
received
no
previous
systemic
treatment.

Pts with
ALKpositive
NSCLC
who had
received
one prior
platinumbased
regimen.

180

RCT

344

22-81

Pts with
ALKpositive
NSCLC
who had
received
one prior
platinumbased
regimen.

Pts with
ALKpositive
NSCLC
who had
received
no
previous
systemic
treatment.

17

Chest pain
was evaluated
using
EORTC
QLQ-LC13
module and
compared
between
crizotinib
treatment and
chemotherapy
treatment.
Chest pain
was evaluated
using
EORTC
QLQ-LC13
module and
compared
between
crizotinib
treatment and
chemotherapy
treatment.
Chest pain
was evaluated
using
EORTC
QLQ-LC13
module and
compared
between
crizotinib
treatment and
chemotherapy
treatment.

Solomon,
2014 (2)

Blackhall,
2014 (3)
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Outcomes Measured
In this review, the primary focus of the outcome was the reduction of chest pain in ALKpositive NSCLC patients with crizotinib treatment or chemotherapy. The European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire 13-item lung cancer module
(EORTC QLQ-LC13) was completed by patients, the scores were used to measure lung cancer
specific symptoms including chest pain.16,17,18 Patient-reported outcomes of the chest pain had a
baseline assessment and at least one post-baseline assessment.16,17,18 The chest pain could also be
caused by other factors such as anxiety or depression, which were not evaluated in this study. The
progression-free survival time was evaluated and will not be discussed in this study.

Results
An open-label, phase 3 trial study conducted by Shaw et al. with 347 ALK-positive NSCLC
patients who had received one prior platinum-based regimen were randomly assigned to receive
crizotinib (250 mg, twice daily) or intravenous chemotherapy – pemetrexed (500 mg per square
meter of body surface area) or docetaxel (75 mg per square meter).16 Among the 347 patients, 173
of them received crizotinib and 174 received chemotherapy.16 Patients in the chemotherapy group
were allowed to cross over to crizotinib as part of a separate study.16
Questionnaires including EORTC QLQ LC-13 to measure patient-reported outcomes
(PRO) were given at day 1 as the baseline and at every 3-week subsequent cycle, the primary end
point was progression-free survival (PFS).16 The chest pain is one of the items in EORTC QLQ
LC-13. PROs were evaluated in patients with a baseline assessment and at least one post treatment
assessment using repeated-measures mixed-effects modeling to compare crizotinib group and
chemotherapy group by the overall change from baseline scores on EORTC QLQ LC-13.16 The

Sun, Crizotinib in ALK-positive NSCLC 6
raw scores were standardized into a range from 0-100 with 100 presenting the highest symptom
severity, every 10 points change from baseline consider as clinically meaningful.20 The mean
reduction in symptom score was measured, the chest pain has a significantly greater reduction
from the baseline in crizotinib group than in chemotherapy group with patients who had one prior
platinum-based regimen (P<0.001; Table 2).16

Table 2. Overall change from baseline in the chest pain.

Mean change from baseline
P<0.001

Crizotinib

Chemotherapy

-12

2

Another similar study was conducted by Solomon et al.; 343 ALK-positive NSCLC patients
who had no previous systemic treatment were randomized to receive crizotinib (250 mg, twice
daily) or intravenous chemotherapy (pemetrexed, 500 mg per square meter of body surface area,
plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5-6 mg
per milliliter per minute).17 Total 172 of the patients were in crizotinib group, and 171 of them
were in chemotherapy group. Crossover to crizotinib treatment from chemotherapy group was
allowed if disease progressed.17 Measurement and data analysis for the chest pain in two different
groups were similar to the first study. The overall change from baseline for the chest pain has a
great reduction in the crizotinib group than in the chemotherapy group with patients had previous
systemic treatment (P<0.001; Table 3).17
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Table 3. Overall change from baseline in the chest pain.
Crizotinib

Chemotherapy

-9

0

Mean change from baseline
P<0.001

The last study by Blackhallet al. included 344 ALK-positive NSCLC patients who had
received one prior platinum-based regimen.18

Patients were randomly assigned to receive

crizotinib (173 patients, 250 mg, twice daily) or intravenous chemotherapy (171 patients,
pemetrexed: 500 mg per square meter or docetaxel: 75 mg per square meter) in a 1:1 ratio.18 No
cross over in the two groups were permitted.18
The scores of questionnaires EORTC QLQ LC-13 were measured and standardized using
the same methods as the last two studies.18 The scores were compared between the crizotinib
group and each of the chemotherapy subgroups (pemetrexed and docetaxel) in: 1. mean change
from baseline; 2. the proportion of patients with improved or worse outcomes.18 Docetaxel and
pemetrexed were associated with a significant worsening of chest pain in comparing with
crizotinib (P<0.001; Table 4).18 In Table 4, a score difference of less than zero indicated crizotinib
favors reduced chest pain, while a score of greater than zero indicated chemotherapy resulted in
less chest pain, and zero value means no difference between crizotinib and chemotherapy. The
chest pain was also found to improve in more patients on crizotinib group than on chemotherapy
group (P<0.001, P<0.05; Table5).18
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Table 4. The estimated difference for chest pain symptoms in the crizotinib group vs. the
chemotherapy group.

Estimated diff. of Chest Pain

Crizotinib vs. Pemetrexed

Crizotinib vs. Docetaxel

-12.54 (-16.71 to -8.37)
(95% CI, P<0.001)

-14.36(-21.18 to -7.53)
(95% CI, P<0.001)

Table 5. The proportion of patients with improvement and worsening in chest pain in the crizotinib
group vs. chemotherapy group.

Chest Pain
Improvement Rates
(P<0.001)
Worsening Rates
(P<0.05)

Crizotinib

Pemetrexed

Docetaxel

40%

28%

15%

8%

21%

39%

Discussion and Conclusion
For advanced NSCLC, palliation of symptoms and improvement in health-related quality
of life are more important when the disease is incurable. Chest pain is one of the major symptoms
of any kind of lung cancer. Platinum-based double-agent chemotherapy was generally the standard
treatment for NSCLC.21 Crizotinib is the first targeted therapy drug designed for ALK-positive
NSCLC.15 Studies indicated in ALK-positive NSCLC patients crizotinib was significantly greater
in reducing lung cancer symptoms including chest pain comparing with chemotherapy, which is
independent of the type of chemotherapy (pemetrexed or docetaxel), the performance status of the
patients, the race of patients, the presence or absence of brain metastases, and previous systematic
treatment or not.16,17,18 Crizotinib treatment also resulted in longer PFS, greater improvement in
global quality of life, but overall survival did not have significant change between crizotinib and
chemotherapy.16,17
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The EORTC tools used in these studies were previously validated to be clinically
significant when there is a 10-point or greater change, the chest pain improvement reported from
these studies are highly clinically relevant.18 The significant improvement of chest pain, as well
as general health status, were observed in crizotinib treatment, but not in either type of
chemotherapy.16,17,18 It is debatable that the outcome report was based on patients’ reports but not
physicians, also patients with the disease were possible more adapted to the symptoms. All these
studies are open-label trials which could potentially cause patients’ bias in their self-report
outcomes based on the different treatment expectation. Different compliance between the two
treatment groups could also be another limitation.
In conclusion, crizotinib demonstrates consistent improvement compared with
chemotherapy (docetaxel or pemetrexed) in chest pain and other key lung cancer symptoms, as
well as on the global quality of life and general health status. As an inhibitor of Met and ALK,
crizotinib has the potential to treat different types of cancers which contain Met or ALK mutations
such as colorectal cancer, liver cancer, or gastric carcinoma. Further research can include the study
of how effective crizotinib is in other type of cancers treatment.

References
1.

Cancercare. lung cancer 101.
https://www.lungcancer.org/find_information/publications/163-lung_cancer_101/268types_and_staging. Published 2019.

2.

ALK gene. Genecards. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ALK.

3.

ALK gene. Genetics home reference. https://ghr.nlm.nih.gov/gene/ALK. Published
November 26, 2019.

4.

What is ALK-positive lung caner? ALK positive. https://www.alkpositive.org/what-is-alk.

5.

Key statistics for lung cancer. http://www.cancer.org/content/cancer/en/cancer/lungcancer/about/key-statistics.html. Published January 2018.

6.

United States cancer statistics: data visualizations. centers for disease control and
prevention. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Published June 2018.

7.

What is ALK-positive lung cancer? And what are the options for treatment? Lung cancer
foundation of America. https://lcfamerica.org/lung-cancer-info/survivors/alk-positive-lungcancer/.

8.

Zappa C, Mousa S. Non-small cell lung cancer: current treatment and future advances.
Transl Lung Cancer Res. 2016;5(3):288-300.

9.

Korytowsky B, Radtchenko J, Nwokeju E, Tuell K, Kish J, Feinberg B. Understanding total
cost of care in advanced non-small cell lung cancer pre- and postapproval of immunooncology therapies. Am J Manag Care. 2018;24(20 Suppl):S439-S447.

10. Lung cancer. Mayo clinic. https://www.mayoclinic.org/diseases-conditions/lungcancer/symptoms-causes/syc-20374620.
11. Radiation therapy for non-small cell lung cancer. American cancer society.
https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/radiation-therapy.html.
12. Chemotherapy for non-small cell lung cancer. American cancer society.
https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/chemotherapy.html.
13. Arbour K, Riely G. Systemic therapy for locally advanced and metastatic non-small cell
lung cancer: a review. JAMA. 2019;322(8):764-774.
14. Cancer immunotherapy. American cancer society.
https://www.cancer.org/treatment/treatments-and-side-effects/treatmenttypes/immunotherapy.html.
15. Shaw A, Yeap B, Camidge D. Effect of crizotinib on overall survival in patients with
advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective

analysis. Lancet Oncol. 2011;12(11):1004-1012.
16. Shaw A, Kim D, Janne P. Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 2013;368(25):2385-2394.
17. Solomon B, Mok T, Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive
lung cancer. N Engl J Med. 2014;371(23):2167-2177.
18. Blackhall F, Kim D, Shaw A. Patient-reported outcomes and quality of life in PROFILE
1007: a randomized trial of crizotinib compared with chemotherapy in previously treated
patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol.
2014;9(11):1625-1633.
19. Eisenhauer E, Therasse P, Verweij J. New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
20. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in
health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144.
21. Schiller J, Harrington D, Johnson D. Comparison of four chemotherapy regimens for
advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.

